<DOC>
	<DOCNO>NCT02162264</DOCNO>
	<brief_summary>To investigate factor affect Aricept medication persistence rate safety efficacy patient Alzheimer 's Disease clinical practice</brief_summary>
	<brief_title>Post-marketing Surveillance Donepezil Hydrochloride -Investigation Factors That Affect Aricept Medication Persistence Rate Safety Efficacy Patients With Alzheimer 's Disease Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion criterion : Patients diagnose Alzheimer 's Disease administer Aricept first time . Exclusion criterion : Patients history hypersensitivity ingredient Aricept piperidine derivative .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>donepezil hydrochloride</keyword>
</DOC>